StockData
Cardiff Oncology, Inc. logo

Cardiff Oncology, Inc. (CRDF) stock

CRDFNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$0.85−0.04 (-4.46%)

Close on Nov 20, 2026Market cap $66.34MP/E –Yield –

Cardiff Oncology price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Cardiff Oncology's price to sales ratio was 103.2× on Nov 11, 2026, against 305.3× a year earlier. Over the last 5 years it ranged from 103.2× to 488.9×, with a median of 199.5×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026103.2×−273.1
2025Dec 31, 2025376.3×+69.4
2024Dec 31, 2024307.0×+163.2
2023Dec 29, 2023143.7×−11.4
2022Dec 30, 2022155.2×+31.9
2020Jul 31, 2020123.3×+88.6
2019Dec 31, 201934.7×+9.6
2018Dec 31, 201825.1×−5.1
2017Dec 29, 201730.2×−133.8
2016Dec 30, 2016163.9×−207.0
2015Oct 30, 2015370.9×+71.0
2014Dec 31, 2014299.9×+10.8
2013Dec 31, 2013289.2×−16.3
2012Dec 31, 2012305.4×–

More Cardiff Oncology figures

See a number that looks wrong?